Effective treatment for DCIS is vital for continued reduction in Australia's breast cancer mortality rate

August 18, 2014 by Joanna Wheatley
Figure 1: Cross-section of a breast duct showing progression from DCIS to invasive breast cancer Credit: Boyages: DCIS of the Breast: Taking Control

Variations in the treatment of DCIS (Ductal Carcinoma In Situ or precancerous cells of the breast) may be a contributing factor in worldwide differences in breast cancer mortality rates according to Professor John Boyages, Director of the Macquarie University Cancer Institute (Figure 1).

The latest statistics from the World Health Organisation show that Australia is still one of the best in the world at reducing the risk of dying from breast cancer. However, although rates in Australia fell by a staggering 35% from 1989 until 2008 there has been no real change in the latest statistics published in December 2013 (Figure 2).

In a new book released today DCIS of the Breast: Taking Control by Professor Boyages, he summarises evidence and explains why he believes that if DCIS is left untreated, that for many patients, invasive cancer will occur given enough time.

DCIS means that abnormal cells are lodged in one or more of the breast ducts but they haven't yet escaped to become potentially lethal breast cancer. Professor Boyages calls this "precancer" and often explains this as a pipe that is very strong on the outside but contains some rust on the inside that has not yet penetrated the surface of the pipe. Will the rust break through the pipe? Maybe, maybe not.

However, Professor Boyages says, "If you do not effectively diagnose and treat DCIS, there is no doubt in my mind, that for many patients, will occur given enough time.

It is therefore vital for patients diagnosed with DCIS through mammography to understand their own risk, however low, of DCIS returning and the chance of it coming back as invasive breast cancer that may require more intensive treatments such as chemotherapy."

There is no doubt about it – treating DCIS is controversial due to the diversity of medical opinion.

Figure 2: Selected mortality rates sorted by Mortality rates (2012) Date released December 2013

About 40 women every day are diagnosed with breast cancer in Australia and an additional four with DCIS. Professor John Boyages, MD, PhD is a radiation oncologist and has over 30 years' experience and is one the world's all-round experts about this complex disease.

In one study he quotes, 11 of the 29 patients (38%) who did not have treatment of supposedly indolent low-grade DCIS, progressed to invasive cancer over a 30-year time period and six of the 11 died from it. In a virtually unnoticed European clinical trial from September 2013, patients with DCIS treated by a lumpectomy had a 31% recurrence in the breast within 15 years after surgery alone and half (15%) of the recurrences were invasive. Of concern, by 20 years, four of every 10 patients with an invasive breast cancer recurrence had died from it.

"In my opinion, many of these deaths could have been prevented" said Professor Boyages. There is a lot of misinformation out there about DCIS. Epidemiologists say it is over diagnosed and over-treated. On the other hand, treatment to the breast (lumpectomy, lumpectomy and radiation, mastectomy), lymph nodes (sample or not) and medications (tamoxifen or not) also varies widely.

Figure 3: Early detection of DCIS and cancer for women in their 50′s reduces mortality for women in the 70′s dashed black line expected; red dash line- observed.

The detection of DCIS and small cancers for women in their 50's and 60's since BreastScreen started in1992 has led to significantly reduced breast cancer incidence and mortality (Figure 3) for women in their 70's from 1994.

Breast screening works by stopping DCIS progressing to invasive breast cancer years later, and finding small, easier to treat, cancers which have not yet spread. However it is also important to effectively treat detected DCIS to reduce future invasive .

Professor Boyages first started treating patients as a specialist oncologist in the late 80's just before coordinated screening programs started in many countries. He said one of the really important initiatives has been the BreastScreen program. Breast screening has acted as a catalyst for doctors to work together in teams, find cancer early and strive to treat it without more difficult treatments such as mastectomy and intensive chemotherapy. However, there is still a lot of variation as to how DCIS is diagnosed and treated based on his large numbers of second opinions he gives for patients with this disease.

It's vital that women have as much information as possible to ensure they get the best conventional treatment but also knowing what they can do for themselves. DCIS of the Breast Taking Control is a 280 page full-colour book and is a must-read. It is a totally comprehensive guide for all with DCIS and their caregivers. It addresses finding the right , common side-effects, newer oncoplastic techniques, the role of sentinel node biopsy and tamoxifen and how to cope with life after diagnosis or if DCIS does recur.

Explore further: New skin gel fights breast cancer without blood clot risk

Related Stories

New skin gel fights breast cancer without blood clot risk

July 15, 2014
A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects that deter some women ...

Breast conserving treatment with radiotherapy reduces risk of local recurrence

September 18, 2013
Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS). ...

New findings could tackle over-diagnosis and over-treatment of breast cancer

December 4, 2013
New research from Queen Mary University of London has revealed, for the first time, the molecule αvβ6 (alpha v beta 6) could tell doctors which cases of Ductal Carcinoma in Situ (DCIS), a condition where non-invasive cancerous ...

Accelerated radiation treatment effective for noninvasive breast cancer

June 29, 2012
Accelerated whole breast irradiation after lumpectomy is an effective treatment for ductal carcinoma in situ (DCIS), a very common early stage and noninvasive form of breast cancer, meaning many more breast cancer patients ...

Terminology used to describe preinvasive breast cancer may affect patients' treatment preferences

August 26, 2013
When ductal carcinoma in situ (DCIS, a preinvasive malignancy of the breast) is described as a high-risk condition rather than cancer, more women report that they would opt for nonsurgical treatments, according to a research ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.